The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial

Mark Weiser, Linda Levi, Shimon Burshtein, Roxana Chiriță, Diana Cirjaliu, Ilan Gonen, Robert Yolken, Michael Davidson, Daisy Zamora, John M. Davis

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Studies have hypothesized that immunological abnormalities might contribute to schizophrenia, and basic science studies, as well as several clinical trials suggest that minocycline could be efficacious in ameliorating both positive and negative symptoms of schizophrenia. In this study we examined the effect of minocycline on schizophrenia in a large randomized controlled trial. Methods: We performed a 16-week, multi-center, double-blind, randomized, placebo-controlled study on 200 subjects with schizophrenia or schizoaffective disorder randomized to receive either minocycline (200 mg/day, n = 100), or placebo (n = 100) as an add-on to anti-psychotic treatment. The primary outcome measure was the PANSS total score. Results: Mixed models for repeated measures showed no significant difference between minocycline and placebo for total PANSS (p = 0.862), PANSS subscales, CGI or BACS. Conclusions: Minocycline did not improve symptoms or cognition in schizophrenia.

Original languageEnglish (US)
Pages (from-to)325-332
Number of pages8
JournalSchizophrenia Research
Volume206
DOIs
StatePublished - Apr 2019

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Fingerprint Dive into the research topics of 'The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial'. Together they form a unique fingerprint.

Cite this